Abstract
Angiogenesis is the base for solid tumour growth and dissemination, and anti-angiogenic drugs have been demonstrated to be active in clinical trials. In addition, it has become increasingly clear that inflammation is a key component in tumour insurgence. Chemo-prevention focuses on the primary or secondary prevention of cancer using natural or synthetic agents that usually show mild or no collateral effects. We have noted that angiogenesis, particularly ‘tory angiogenesis’, is a common target of many chemopreventive molecules, where they most likely suppress the angiogenic switch in pre-malignant tumours, a concept we have termed ‘angioprevention’. We have shown that various molecules, such as flavonoids, anti-oxidants and retinoids, act in the tumour microen-vironment inhibiting the recruitment and/or activation of endothelial cells and phagocytes of the innate immunity. We have recently assessed the activity of novel compounds derived from the oleanolic acid triterpenoid, called CDDO-Me and CDDO-Imm. These compounds show a potent anti-angiogenic activity at low dosages. In vivo they inhibit angiogenesis in the Matrigel sponge assay and in KS-Imm (an immortalized Kaposi's sarcoma cell line) tumour growth. In vitro they are able to prevent endothelial cell tubulogenesis when cultured on Matrigel. In human umbilical vein endothelial (HUVE) cells these compounds can inhibit the activation of the extracellular signal-regulated kinase ERK1/2 pathway after stimulation with vascular endothelial growth factor (VEGF). Moreover, from immunofluorescence experiments we observed that treatment with these triterpenoids prevents nuclear factor NF-κB translocation into the nucleus and thereby the activation of downstream pathways. The particularly potent anti-angiogenic activity seen in vivo suggest that CDDO-Me may be interacting with an important network of molecular and cellular targets, on endothelial cells, and could be employed for ‘angioprevention’. These substances are being assessed in phase I trials in humans in the United States.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Albini A, Sporn MB (2007) The tumour micro-environment as a target for chemoprevention. Nat Rev Cancer 7:139–147
Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407
Brigati C, Noonan DM, AlbiniI A, Benelli R (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19:247–258
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186
Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC (2005) Synthetic triterpe-noids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65:4799–4808
Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, Madden T, Andreeff M (2003) Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apop-tosis in breast cancer cells. Cancer Res 63: 5926–5939
McDonald DM, Baluk P (2002) Significance of blood vessel leakiness in cancer. Cancer Res 62:5381–5385
Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB (2006) A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemo-therapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 12:1828–1838
Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Subbaramaiah K, Sporn MB (1999) A novel synthetic oleanane triterpe-noid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiprolifera-tive, and anti- inflammatory activity. Cancer Res 59:336–341
Tosetti F, Ferrari N, De Flora S, Albini A (2002) Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16:2–14
Vannini N, Lorusso G, Cammarota R, Barberis M, Noonan DM, Sporn MB, Albini A (2007) The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol Cancer Ther 6:3139–3146
Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY (2004) c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1,9-dien-28-oate in human lung cancer cells. Cancer Res 64:7570–7578
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sogno, I. et al. (2009). Anti-angiogenic Activity of a Novel Class of Chemopreventive Compounds: Oleanic Acid Terpenoids. In: Senn, HJ., Kapp, U., Otto, F. (eds) Cancer Prevention II. Recent Results in Cancer Research, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69297-3_19
Download citation
DOI: https://doi.org/10.1007/978-3-540-69297-3_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69296-6
Online ISBN: 978-3-540-69297-3
eBook Packages: MedicineMedicine (R0)